Management of Persistent Muscle Pain After Statin Discontinuation

Introduction to Statin-Associated Muscle Symptoms

The American College of Cardiology recommends that if muscle symptoms persist beyond 2 months after statin cessation, clinicians should consider other causes of muscle symptoms, as these symptoms are unlikely to be statin-related 1, 2
Most true statin-associated muscle symptoms resolve within weeks of discontinuation, and the 2-month threshold is a key decision point for investigating alternative causes 1, 2, 3

The American College of Cardiology suggests evaluating for non-statin causes of myopathy, including assessing creatine kinase (CK) levels to evaluate for ongoing muscle damage 1, 3
Thyroid-stimulating hormone (TSH) levels should be checked, as hypothyroidism is a common cause of myopathy that predisposes to statin intolerance 3, 4
25-hydroxyvitamin D levels should be assessed, as vitamin D deficiency can cause myopathy and increase statin-related muscle symptoms 3, 4
A comprehensive metabolic panel should be performed to assess renal and hepatic function 3, 4
Anti-HMGCR antibodies should be tested, particularly in patients with an unclear autoimmune history, to evaluate for statin-associated autoimmune myopathy (SAAM) 3

The American College of Cardiology recommends that patients with SAAM should be referred to a neurologist specializing in neuromuscular disorders and receive immunosuppressive therapy directed at the autoimmune process 3

If symptoms are statin-related and resolve, rechallenge with a different statin at the lowest dose to establish causality and attempt to achieve cardiovascular risk reduction 1, 3
If symptoms persist beyond 2 months, resume statin therapy at the original dose once the underlying condition is identified and treated, as the cardiovascular risk from untreated atherosclerosis far exceeds the risk of appropriately managed statin therapy 1, 3

The American College of Cardiology recommends targeting LDL-C <55 mg/dL (<1.4 mmol/L) for patients with established atherosclerotic cardiovascular disease 6
Combination therapy with ezetimibe plus PCSK9 inhibitors or bempedoic acid should be pursued if statins cannot be tolerated 6